IRIS
SANTONI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.799
EU - Europa 2.334
AS - Asia 1.025
AF - Africa 143
Continente sconosciuto - Info sul continente non disponibili 5
SA - Sud America 5
OC - Oceania 3
Totale 10.314
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.797
UA - Ucraina 466
IT - Italia 409
IE - Irlanda 388
SE - Svezia 381
SG - Singapore 363
CN - Cina 317
DE - Germania 247
TR - Turchia 176
DK - Danimarca 158
CI - Costa d'Avorio 128
FI - Finlandia 107
GB - Regno Unito 95
KR - Corea 91
IN - India 61
FR - Francia 41
BE - Belgio 18
MA - Marocco 14
NL - Olanda 6
EU - Europa 5
AU - Australia 3
ID - Indonesia 3
RU - Federazione Russa 3
BG - Bulgaria 2
BO - Bolivia 2
BR - Brasile 2
ES - Italia 2
LU - Lussemburgo 2
PK - Pakistan 2
RS - Serbia 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AZ - Azerbaigian 1
CA - Canada 1
CZ - Repubblica Ceca 1
EG - Egitto 1
HK - Hong Kong 1
IL - Israele 1
IM - Isola di Man 1
IS - Islanda 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LV - Lettonia 1
MX - Messico 1
MY - Malesia 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
PL - Polonia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 10.314
Salva come PNG Salva come JPEG
Città #
Chandler 858
Fairfield 706
Des Moines 686
Jacksonville 528
Ashburn 475
Dublin 386
Wilmington 378
Boardman 321
Woodbridge 306
Seattle 269
Houston 247
New York 201
Cambridge 195
Lawrence 160
Princeton 160
San Mateo 153
Singapore 146
Abidjan 128
Ann Arbor 126
Centro 98
San Diego 78
Pune 56
Washington 39
Turin 38
Beijing 35
London 33
Marche 33
Los Angeles 28
Helsinki 27
Guangzhou 26
Redmond 26
Ancona 22
Dallas 22
Falls Church 22
Norwalk 20
Shanghai 20
Wuhan 19
Brussels 16
Jiaxing 14
Kilburn 11
Rome 10
Wuxi 9
Hounslow 8
Izmir 8
Squinzano 8
Nanjing 7
Prescot 7
Chengdu 6
Chiswick 6
Porto 6
Strasbourg 6
Yiwu 6
Seoul 5
Tolentino 5
Zhengzhou 5
Chicago 4
Edinburgh 4
Fayetteville 4
Frankfurt am Main 4
Milan 4
Santa Clara 4
Shenzhen 4
Wandsworth 4
Berlin 3
Buffalo 3
Clifton 3
Jinhua 3
Macerata 3
Marano di Valpolicella 3
Modena 3
Phoenix 3
Portland 3
Redwood City 3
Stockholm 3
Torre Del Greco 3
Augusta 2
Chongqing 2
Città di Castello 2
Fuzhou 2
Hanoi 2
Heze 2
Islamabad 2
Isola della Scala 2
Jesi 2
Jinan 2
La Paz 2
Luxembourg 2
Montechiarugolo 2
Montelupone 2
Mumbai 2
Nantong 2
Newark 2
Palermo 2
Rapagnano 2
San Benedetto del Tronto 2
San Biagio 2
San Severino Marche 2
Segrate 2
Sofia 2
Southwark 2
Totale 7.332
Salva come PNG Salva come JPEG
Nome #
Designing novel immunocombinations in metastatic renal cell carcinoma 152
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 128
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 116
Microbiome and cancers, with focus on genitourinary tumors 107
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 107
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 106
Metabolic phenotype of bladder cancer 105
Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses 104
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 103
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 103
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 102
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 100
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 99
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 98
KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma 94
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 94
Metabolic Alterations in Renal and Prostate Cancer 93
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 92
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 91
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 89
Is There a Role for Immunotherapy in Prostate Cancer? 89
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 87
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 85
Hyponatremia in cancer patients: Time for a new approach 85
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 85
HER family receptor expression and prognosis in pancreatic cancer 84
Predicting future cancer burden in the United States by artificial neural networks 84
Pd-l1 inhibitors for the treatment of prostate cancer 84
Exploring the Spectrum of Kidney Ciliopathies 83
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 81
Urinary catheters and biofilm formation 79
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 79
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 79
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 79
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 79
Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy 78
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 78
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 78
Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report 78
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 78
The route to personalized medicine in bladder cancer: where do we stand? 77
Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials 76
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 75
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 74
High CTLA-4 expression correlates with poor prognosis in thymoma patients 74
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 73
Molecular characterization of testicular germ cell tumors using tissue microdissection 73
Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date 72
Metabolic alterations in renal cell carcinoma 72
Present and future of personalized medicine in adult genitourinary tumors 72
IMPACT OF VEGF, VEGFR, PDGFR, HIF AND ERCC1 GENE POLYMORPHISMS ON THYMIC MALIGNANCIES OUTCOME 72
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 72
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 72
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 71
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 71
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 71
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 70
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 70
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 70
Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Protein in Urothelial Cell Carcinoma of Human Bladder 69
Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. 69
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors 69
Trattamento del carcinoma del pancreas. Attualità e prospettive 69
Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients 69
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 69
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 69
Quick steps toward precision medicine in renal cell carcinoma 69
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 69
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 69
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 68
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 68
Re: Epithelial-to-mesenchymal transition in renal neoplasms 67
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 67
Immunotherapy and radiation therapy in renal cell carcinoma 67
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 67
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 66
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 66
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 66
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 66
AR-V7 and prostate cancer: The watershed for treatment selection? 65
Emerging Immunotargets and Immunotherapies in Prostate Cancer 65
null 64
Treating prostate cancer by antibody-drug conjugates 64
Editorial: Emerging biomarkers in genitourinary tumors 63
The identification of immunological biomarkers in kidney cancers 63
Epigenetic modulations and lineage plasticity in advanced prostate cancer 63
Renal Cell Carcinoma: genomic landscape and clinical implications 63
Bone targeting agents in patients with metastatic prostate cancer: State of the art 63
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 62
null 62
The origin of prostate metastases: emerging insights 61
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma 61
Bladder cancer: molecular determinants of personalized therapy 61
Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies 60
Role of STAT3 pathway in genitourinary tumors 59
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 59
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. 58
Recent aspects of Sunitinib therapy in patients with metastatic clear-cell Renal Cell Carcinoma: a systematic review of the litherature. 58
Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. 58
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 58
Totale 7.740
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.469
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.469
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020374 0 0 0 0 0 1 94 2 98 21 30 128
2020/20212.580 140 151 236 15 242 512 268 200 196 277 273 70
2021/20221.351 200 208 40 24 26 142 33 65 104 118 134 257
2022/20232.870 240 271 149 214 151 879 6 156 586 13 152 53
2023/20241.409 239 34 99 163 204 362 30 41 4 31 17 185
2024/2025786 330 209 32 18 108 89 0 0 0 0 0 0
Totale 10.573